Influenza Vaccination in Cancer Patients Undergoing Systemic Therapy

Abstract

BACKGROUNDCancer patients often experience preventable infections, including influenza A and B. These infections can be a cause of significant morbidity and mortality. The increased risk of infection may be because of either cancer itself or treatment-induced immunosuppression.1 Influenza immunization has been shown to decrease the risk of influenza infection in patients with intact immunity.2 In cancer patients, active immunization has been shown to confer protective immunity against several infections at similar rates to healthy individuals, which has translated into decreased duration and severity of infection and potentially improved morbidity and mortality.3OBJECTIVESTo assess the efficacy of influenza vaccination in stimulating immunological response in patients with cancer during chemotherapy compared to control groups.To assess the efficacy of influenza vaccination in preventing confirmed influenza and influenza-like illness and/or stimulating immunological response in children with cancer treated with chemotherapy, compared to placebo, no intervention, or different dosage schedules.To determine the adverse effects associated with influenza vaccination in patients with cancer.SEARCH METHODSWe searched MEDLINE/PubMed database for articles published from 1964 to 2013 using the search terms “cancer,” “adult,” “influenza vaccination,” and “chemotherapy.”SELECTION CRITERIAWe included studies based on systematic sampling with defined clinical criteria irrespective of the vaccination status of cancer patients. Studies measure the serological response or clinical response to compare between the study group and the control group. Studies assessed the inactivated influenza vaccines and live attenuated influenza vaccine (LAIV) protective serological reaction and the clinical outcomes after vaccination.DATA COLLECTION AND ANALYSISTwo independent authors assessed the methodological quality of included studies and extracted data.MAIN RESULTSWe included 16 studies (total number of participants = 1,076). None of the included studies reported clinical outcomes. All included studies reported on influenza immunity and adverse reaction on vaccination. We included 6 solid tumor studies and 10 hematological studies. In 12 studies, the serological response to influenza vaccine was compared in patients receiving chemotherapy (n = 425) versus those not receiving chemotherapy (n = 376). In three studies, the serological responses to influenza vaccination in patients receiving chemotherapy are compared to that in healthy adult. Measures used to assess the serological responses included a four-fold rise increase in antibody titer development of hemagglutination inhibition (HI) titer >40, and pre- and post-vaccination geometric mean titers (GMTs). Immune responses in patients receiving chemotherapy were consistently weaker (four-fold rise of 17–52%) than in those who had completed chemotherapy (50–83%) and healthy patients (67–100%). Concerning adverse effects, oncology patients received influenza vaccine, and the side effects descri...

Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach

“…A German study that included 203 patients who had influenza along with haematologic and solid tumours reported a high rate of pneumonia and bacterial or fungal superinfections . Influenza also appears to have a detrimental impact on the outcome of cancer treatment by delaying the initiation of anticancer therapy …”

Mapping Host-Related Correlates of Influenza Vaccine-Induced Immune Response: An Umbrella Review of the Available Systematic Reviews and Meta-Analyses

“…Agarwal et al [43] concluded that approximately 50% of the primary studies included had indicated a negative effect of IV in patients using immunosuppressive medications. Three SRs [46,51,60] involving cancer patients (either pediatric or adult) advocated the use of IVs in such patients, although uncertainty regarding the negative effect of the condition was substantial. Finally, the SR by Sousa et al [59] on the effect of rheumatic diseases on IV immunogenicity concluded that the biological therapy of rheumatic diseases could hamper the immune response, but that IV could be beneficial in such patients.…”

A multiyear quality improvement project to increase influenza vaccination in a pediatric oncology population undergoing active therapy

“…An alternative approach is to use standardized quality improvement (QI) processes to drive outcomes . Achieving and sustaining a high annual vaccination rate in an entire pediatric cancer population undergoing active therapy is an approach that has merit based on the safety of the inactivated influenza vaccine in the immunocompromised population, and the expectation that an immune response to vaccination, even a partial response, may reduce the severity of an infection …”

“…undergoing active therapy is an approach that has merit based on the safety of the inactivated influenza vaccine in the immunocompromised population, and the expectation that an immune response to vaccination, even a partial response, may reduce the severity of an infection. 9…”